BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25963988)

  • 21. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Hope WW; Walsh TJ
    Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis.
    Undre N; Stevenson P; Baraldi E
    Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):31-8. PubMed ID: 21956255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.
    Benjamin DK; Deville JG; Azie N; Kovanda L; Roy M; Wu C; Arrieta A
    Pediatr Infect Dis J; 2013 Nov; 32(11):e419-25. PubMed ID: 23958810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
    Undre NA; Stevenson P; Freire A; Arrieta A
    Pediatr Infect Dis J; 2012 Jun; 31(6):630-2. PubMed ID: 22301478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!
    Gumbo T
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S635-42. PubMed ID: 26567282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease.
    Bochennek K; Balan A; Müller-Scholden L; Becker M; Farowski F; Müller C; Groll AH; Lehrnbecher T
    J Antimicrob Chemother; 2015 May; 70(5):1527-30. PubMed ID: 25564562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
    Autmizguine J; Hornik CP; Benjamin DK; Brouwer KL; Hupp SR; Cohen-Wolkowiez M; Watt KM
    Pediatr Infect Dis J; 2016 Nov; 35(11):1204-1210. PubMed ID: 27314826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
    Maseda E; Grau S; Villagran MJ; Hernandez-Gancedo C; Lopez-Tofiño A; Roberts JA; Aguilar L; Luque S; Sevillano D; Gimenez MJ; Gilsanz F
    J Antimicrob Chemother; 2014 Jun; 69(6):1624-32. PubMed ID: 24505092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of an elevated dosage of micafungin in premature neonates.
    Smith PB; Walsh TJ; Hope W; Arrieta A; Takada A; Kovanda LL; Kearns GL; Kaufman D; Sawamoto T; Buell DN; Benjamin DK
    Pediatr Infect Dis J; 2009 May; 28(5):412-5. PubMed ID: 19319022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants.
    Kawada M; Fukuoka N; Kondo M; Okazaki K; Kusaka T; Kawada K; Itoh S
    Pediatr Infect Dis J; 2009 Sep; 28(9):840-2. PubMed ID: 19636279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
    Hiemenz J; Cagnoni P; Simpson D; Devine S; Chao N; Keirns J; Lau W; Facklam D; Buell D
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1331-6. PubMed ID: 15793107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Oshima K; Kanda Y; Kako S; Ohno K; Kishino S; Kurokawa M
    Transpl Infect Dis; 2013 Jun; 15(3):323-7. PubMed ID: 23578224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yoshikawa K; Nakazawa Y; Katsuyama Y; Hirabayashi K; Saito S; Shigemura T; Tanaka M; Yanagisawa R; Sakashita K; Koike K
    Infection; 2014 Aug; 42(4):639-47. PubMed ID: 24567233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin.
    Krishna G; Vickery D; Ma L; Yu X; Noren C; Power E; Beresford E; Medlock M
    J Clin Pharmacol; 2011 Jan; 51(1):84-92. PubMed ID: 20489029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
    Groll AH; Mickiene D; Petraitis V; Petraitiene R; Ibrahim KH; Piscitelli SC; Bekersky I; Walsh TJ
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3322-7. PubMed ID: 11709303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.
    Liu X; Liu D; Pan Y; Li Y
    J Clin Pharm Ther; 2020 Dec; 45(6):1207-1217. PubMed ID: 32672361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections.
    Garbez N; Mbatchi L; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0230720. PubMed ID: 33846133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bronchopulmonary disposition of micafungin in healthy adult volunteers.
    Nicasio AM; Tessier PR; Nicolau DP; Knauft RF; Russomanno J; Shore E; Kuti JL
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1218-20. PubMed ID: 19114675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Why might micafungin be the drug of choice in pediatric patients?].
    Ramos Amador JT; Prieto Tato L; Guillén Martín S
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.